Literature DB >> 2846525

Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.

C L Lucore1, S Fujii, T C Wun, B E Sobel, J J Billadello.   

Abstract

To identify factors potentially influencing expression of type 1 plasminogen activator inhibitor (PAI-1), we characterized the human tissue-specific distribution of PAI-1 mRNA and the influence of epidermal growth factor (EGF) on expression of steady state levels of PAI-1 mRNA and secretion of PAI-1 by Hep G2 cells. Two species of PAI-1 mRNA (3.2 and 2.2 kilobases) were detected, and the ratio of the two varied among tissues (3 to 5:1) in contrast to the 1:1 ratio detected in Hep G2 cells. Expression of PAI-1 mRNA was inversely related to the distribution of tissue-type plasminogen activator mRNA (2.3 kilobases). Nu-Serum, a growth media supplement, increased steady state levels of PAI-1 mRNA 5-fold within 3 h. Factors responsible were found to be trypsin-sensitive and dialysis-resistant. Antisera to EGF attenuated Nu-Serum-induced increases of PAI-1 mRNA by 57%, suggesting that EGF or EGF homologous peptides contributed to the response. EGF elicited increases of PAI-1 mRNA levels in a dose-dependent manner. Induction was rapid (7-fold at 3 h with 5 ng/ml) and complete within 10 h. The response was not attenuated by cycloheximide (25 micrograms/ml). Factor X and glyceraldehyde-3-phosphate dehydrogenase mRNA did not increase. Increased levels of PAI-1 antigen were detected in conditioned media of Hep G2 cells by 4 h and were maximal at 8 h (6-fold). We conclude that the expression of PAI-1 mRNA is tissue-specific and regulated by epidermal growth factor in Hep G2 cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846525

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

3.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

4.  Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor.

Authors:  W E Hopkins; D R Westerhausen; B E Sobel; J J Billadello
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

5.  Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.

Authors:  D J Schneider; B E Sobel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

6.  Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.

Authors:  J Schneiderman; M Sawdey; H Craig; T Thinnes; G Bordin; D J Loskutoff
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

8.  Species-specific differential cleavage and polyadenylation of plasminogen activator inhibitor type 1 hnRNA.

Authors:  P G Fattal; J J Billadello
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

9.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.

Authors:  P Eriksson; B Kallin; F M van 't Hooft; P Båvenholm; A Hamsten
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

10.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

Authors:  M S Sawdey; D J Loskutoff
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.